ArticleBMC nephrology2026
Multimodal MRI-based two-stage artificial intelligence framework for renal fibrosis classification in chronic kidney disease.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal fibrosis (RF) is a key pathological hallmark and prognostic indicator of chronic kidney disease (CKD). Accurate evaluation of RF is critical for risk stratification and therapeutic decision-making, yet the current assessment relies mainly on renal biopsy, which has several limitations. This study aimed to develop a two-stage artificial intelligence framework that integrates multimodal MRI (native T1 mapping, ADC, and T2* mapping) and clinical indicators for the noninvasive assessment of RF in patients with CKD.
methodsThis prospective study included 152 patients with biopsy-proven CKD (RF 1: no RF, 34 patients; RF 2: mild RF, 69 patients; and RF 3: moderate to severe RF, 49 patients). The dataset was randomly partitioned into training and test cohorts at a 2:1 ratio. A two-stage model combining MobileNetV2-SE-based deep learning features with clinical indicators was developed for RF classification. Two binary tasks were performed: RF presence (RF 1 vs. RF 2 and RF 3) and severity (RF 2 vs. RF 3). Nested cross-validation was applied for model development and hyperparameter tuning, and bootstrapping was used to assess performance robustness. Model performance was evaluated with the area under the curve (AUC), calibration curves, decision curve analysis (DCA), and SHapley Additive exPlanations (SHAP) visualization.
resultsCompared with single-modality models, the multimodal deep learning model (DL-combine), which is based exclusively on native T1 mapping, ADC, and T2* mapping, demonstrated favourable and stable performance (test AUC: 0.930). Among the 14 classifiers, XGBoost performed numerically better in terms of RF presence (mean AUCs: 0.986, 0.887; accuracy: 0.947, 0.829), whereas ExtraTree performed better in terms of RF severity assessment (mean AUCs: 0.935, 0.883; accuracy: 0.886, 0.848). Calibration curves and DCA confirmed robust predictive reliability and clinical utility. SHAP analysis highlighted the relative contributions of the DL-sign and eGFR.
conclusionThis two-stage multimodal MRI-based framework provides accurate and interpretable assessment of RF across different stages of CKD, supporting noninvasive risk stratification and complementary clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.